Pfizer and BioNTech today announced that their COVID-19 vaccine was 100% effective and triggered a robust antibody response in a phase 3 US trial involving 2,260 adolescents 12 to 15 years old.
The immune responses in that age-group, the companies said, exceeded those recorded previously among 16- to 25-year-olds.The companies say they plan to submit the data to the US Food and Drug Administration for emergency use authorization of the vaccine in this age-group."The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant," BioNTech CEO Ugur Sahin said in